The Parkinson’s disease-associated gene ITPKB protects against α-synuclein aggregation by regulating ER-to-mitochondria calcium release

share:

Brief intro:

  • Author: Daniel J. Apicco, Evgeny Shlevkov, Catherine L. Nezich, David T. Tran, Edward Guilmette, Justin W. Nicholatos, Collin M. Bantle, Yi Chen, Kelly E. Glajch, Neeta A. Abraham, Lan T. Dang, G. Campbell Kaynor, Ellen A. Tsai, Khanh-Dung H. Nguyen, Joost Groot, YuTing Liu, Andreas Weihofen, Jessica A. Hurt, Heiko Runz, and Warren D. Hirsta
  • Journal: Journal of Medicinal Chemistry
  • Doi: https://www.doi.org/10.1073/pnas.2006476118
  • Publication Date: 2020 Dec 21

Products/Services used in the paper

Quotation shows PackGene:Plasmids were then shipped to Packgene Biotech (Worcester, MA) for cloning into AAV entry vectors under the CAG promoter followed by packaging into AAV using the PHP.B serotype.

Research Field:CNS

AAV Serotype:PHP.B

Request Quote

Abstract

Inositol-1,4,5-triphosphate (IP3) kinase B (ITPKB) is a ubiquitously expressed lipid kinase that inactivates IP3, a secondary messenger that stimulates calcium release from the endoplasmic reticulum (ER). Genome-wide association studies have identified common variants in the ITPKB gene locus associated with reduced risk of sporadic Parkinson’s disease (PD). Here, we investigate whether ITPKB activity or expression level impacts PD phenotypes in cellular and animal models. In primary neurons, knockdown or pharmacological inhibition of ITPKB increased levels of phosphorylated, insoluble α-synuclein pathology following treatment with α-synuclein preformed fibrils (PFFs). Conversely, ITPKB overexpression reduced PFF-induced α-synuclein aggregation. We also demonstrate that ITPKB inhibition or knockdown increases intracellular calcium levels in neurons, leading to an accumulation of calcium in mitochondria that increases respiration and inhibits the initiation of autophagy, suggesting that ITPKB regulates α-synuclein pathology by inhibiting ER-to-mitochondria calcium transport. Furthermore, the effects of ITPKB on mitochondrial calcium and respiration were prevented by pretreatment with pharmacological inhibitors of the mitochondrial calcium uniporter complex, which was also sufficient to reduce α-synuclein pathology in PFF-treated neurons. Taken together, these results identify ITPKB as a negative regulator of α-synuclein aggregation and highlight modulation of ER-to-mitochondria calcium flux as a therapeutic strategy for the treatment of sporadic PD.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download